Actinium Pharmac Stock Price, News & Analysis

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is a biopharmaceutical company focused on the development of targeted radiotherapies for patients with advanced cancers. The company describes itself as a pioneer in targeted radiotherapies intended to meaningfully improve patient outcomes, using the alpha‑emitting radioisotope Actinium‑225 (Ac‑225) to deliver highly potent radiation directly to cancer cells while aiming to limit exposure to normal tissues.

According to Actinium’s public disclosures and investor communications, the company’s pipeline is built around antibody‑based constructs that carry Ac‑225 to specific tumor‑associated targets. These programs span both solid tumors and hematologic malignancies, with an emphasis on treatment‑resistant disease settings where existing standards of care often fail.

Core Programs and Pipeline Focus

Actinium identifies ATNM‑400 as its lead solid tumor product candidate. ATNM‑400 is described as a first‑in‑class, multi‑indication Ac‑225 targeted radiotherapy in development for metastatic castration‑resistant prostate cancer (mCRPC), non‑small cell lung cancer (NSCLC) and breast cancer. Across multiple company press releases, ATNM‑400 is characterized as an antibody radioconjugate that targets a distinct, non‑PSMA antigen in prostate cancer and a disease‑driving antigen overexpressed in NSCLC and breast cancer, including in treatment‑resistant settings.

Preclinical data reported by Actinium indicate that ATNM‑400 has shown:

• Potent anti‑tumor activity and durable tumor control in prostate cancer models, including tumors resistant to androgen receptor pathway inhibitors (ARPIs) such as enzalutamide and PSMA‑targeted radiotherapies such as 177Lu‑PSMA‑617 (the active agent in Pluvicto®).
• Superior tumor growth inhibition compared with approved EGFR‑targeted therapies in EGFR‑mutant NSCLC models, and synergistic activity when combined with the EGFR tyrosine kinase inhibitor osimertinib (TAGRISSO®).
• Robust anti‑tumor activity in breast cancer models across hormone receptor‑positive, HER2‑positive and triple‑negative subtypes, including models resistant to tamoxifen and trastuzumab.

These preclinical findings, as described in Actinium’s news releases, support the company’s stated intention to develop ATNM‑400 as a pan‑tumor targeted radiotherapy with potential use as monotherapy, in combination with standard‑of‑care agents, or in sequential treatment strategies after patients progress on existing therapies.

Hematology and Bone Marrow Transplant‑Related Programs

Beyond solid tumors, Actinium’s most advanced clinical‑stage product candidate is Actimab‑A, a CD33‑targeting therapeutic that uses an Ac‑225 payload. Company communications describe Actimab‑A as a potential backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies. In relapsed or refractory AML, Actimab‑A has been reported in Actinium’s releases to show activity in combination with the chemotherapy regimen CLAG‑M, including high rates of complete remission and measurable residual disease (MRD) negativity, and is being advanced toward a pivotal Phase 2/3 trial.

Actinium has also disclosed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to further develop Actimab‑A in AML and other myeloid malignancies. The first trial under this CRADA is planned to evaluate a triplet regimen of Actimab‑A, the Bcl‑2 inhibitor venetoclax, and the oral hypomethylating agent ASTX‑727 in frontline AML patients, according to the company’s statements.

In the conditioning space for cellular and gene therapies, Actinium is developing Iomab‑ACT as a next‑generation targeted conditioning agent with the stated goal of improving patient access and outcomes for potentially curative cell and gene therapies. The company also highlights Iomab‑B as an induction and conditioning agent prior to bone marrow transplant in patients with relapsed or refractory AML, for which it is seeking a strategic partner for U.S. development.

Technology Platform and Intellectual Property

Actinium’s programs are built on a platform that couples monoclonal antibodies or other targeting vehicles with Ac‑225. Across multiple disclosures, the company emphasizes several recurring features of this approach:

• Use of Ac‑225 alpha particles, which are described as delivering high‑linear‑energy‑transfer radiation that induces irreparable double‑strand DNA breaks.
• A shorter tissue path length of alpha emissions compared with beta emitters such as Lutetium‑177, which Actinium states may reduce off‑target toxicity.
• Tumor‑specific uptake and rapid clearance from normal tissues observed in preclinical biodistribution and imaging studies for ATNM‑400.

Actinium reports that it holds on the order of hundreds of patents and patent applications worldwide, including patents related to Ac‑225 manufacturing in a cyclotron and to its various product candidates. In one recent article and several press releases, the company cites approximately 240 to approximately 250 issued and pending patents globally.

Oncology Indications and Unmet Needs

In its public communications, Actinium repeatedly frames its development strategy around large oncology indications with substantial unmet need. These include:

• Metastatic castration‑resistant prostate cancer (mCRPC), where many patients either lack PSMA expression or develop resistance to PSMA‑targeted radioligand therapies and ARPIs.
• EGFR‑mutant NSCLC, where resistance to EGFR TKIs such as osimertinib typically emerges within a few years.
• Breast cancer, particularly hormone receptor‑positive and HER2‑positive disease that relapses after endocrine or HER2‑targeted therapies, and triple‑negative breast cancer, which is associated with poor outcomes.
• Acute myeloid leukemia and other myeloid malignancies, where durable remissions remain challenging in relapsed or refractory settings and in older or unfit patients.

Actinium’s disclosures often reference the commercial performance of existing therapies in these areas (for example, Pluvicto®, Xtandi®, TAGRISSO®, and HER2‑targeted agents) to illustrate the scale of the markets and the persistence of treatment resistance, while positioning its Ac‑225 programs as potential options for patients who have progressed on or are not candidates for current standards of care.

Regulatory Filings and Corporate Governance

Actinium Pharmaceuticals, Inc. is incorporated in Delaware and files reports with the U.S. Securities and Exchange Commission (SEC). The company’s shares of common stock trade on the NYSE American under the ticker symbol ATNM. Recent SEC filings, including its definitive proxy statement and Form 8‑K, describe a typical public company governance structure with a classified board, annual meetings of stockholders, and advisory votes on executive compensation and auditor ratification.

In a Form 8‑K dated November 26, 2025, the company reported the election of two Class III directors at its annual meeting and the approval of proposals including the ratification of its independent registered public accounting firm and an advisory vote on executive compensation. The definitive proxy statement filed on November 5, 2025 provides additional detail on board committees, director elections, and matters submitted to stockholders.

Research and Development Orientation

Across its communications, Actinium emphasizes that its efforts are primarily focused on research and development of Ac‑225‑based radiotherapies. Many of the data cited by the company are preclinical, involving in vitro studies and animal models. Actinium also highlights ongoing and planned clinical development for Actimab‑A and its conditioning agents, as well as its intention to move ATNM‑400 into clinical trials in prostate cancer, NSCLC and breast cancer.

Because the company’s programs are in various stages of development, Actinium’s statements frequently discuss potential mechanisms, preclinical efficacy, and theoretical clinical applications rather than approved indications. Investors and other stakeholders typically review the company’s SEC filings, scientific conference presentations, and press releases to track progress in these programs over time.